MED2005 + Nitrostat 0.6Mg Sublingual Tablet + Nitro Pohl
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
Nov 15, 2017 → Apr 16, 2018
NCT ID
NCT04008732About MED2005 + Nitrostat 0.6Mg Sublingual Tablet + Nitro Pohl
MED2005 + Nitrostat 0.6Mg Sublingual Tablet + Nitro Pohl is a phase 1 stage product being developed by Futura Medical for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT04008732. Target conditions include Erectile Dysfunction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04008732 | Phase 1 | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo | Yuhan | Phase 2 | 52 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 85 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 41 |
| LY2452473 + Tadalafil + LY900010 | Eli Lilly | Phase 1 | 33 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil | Eli Lilly | Phase 3 | 77 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 52 |
| Tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + placebo | Eli Lilly | Approved | 85 |
| Tadalafil + Sildenafil Citrate | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 85 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 77 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| dapoxetine | Johnson & Johnson | Phase 3 | 77 |